A prospective study of the risk of transfusion‐acquired viral infections

Department of Laboratory Medicine, University of California San Francisco 94143-0884, USA.
Transfusion Medicine (Impact Factor: 1.65). 10/1998; 8(3):173-8. DOI: 10.1046/j.1365-3148.1998.00148.x
Source: PubMed


The risk of transfusion-transmitted viral infections may be estimated by several methods, but only prospective studies of transfusion recipients can directly measure the incidence, with associated 95% upper confidence bound, of these infections. From 1989 through 1995, 764 recipients of allogeneic or autologous red blood cell transfusions were enrolled; 486 (64%) provided both pretransfusion and 6-month follow-up specimens. Both specimens were tested for anti-HBc, anti-HCV, anti-HTLV-I and anti-HIV, with appropriate confirmatory testing. Thirty-nine (8.0%) subjects had seroprevalent anti-HBc, 19 (3.9%) subjects had seroprevalent anti-HCV, three (0.6%) subjects had seroprevalent anti-HTLV-I/II, and one (0.2%) subject had seroprevalent anti-HIV. There were no seroconversions for any agent among the 34 patients who received only autologous blood, and no confirmed seroconversions for anti-HTLV-I or anti-HIV among all subjects. There were three seroconversions for anti-HBc (incidence 1.04 x 10(-3); 95% confidence interval (CI) 2.15 x 10(-4), 3.05 x 10(-3) per allogeneic unit transfused), and two confirmed seroconversions for HCV (incidence 6.94 x 10(-4); 95% CI 8.34 x 10(-5), 2.51 x 10(-3) per allogeneic unit transfused). One of the two anti-HCV seroconversions occurred in March 1994, after the institution of HCV EIA 2.0 screening of donated blood. Transfusion-associated seroconversions to hepatitis B and C markers were observed at low rates in the early 1990s despite testing donors for markers of both viruses, whereas seroconversions to HTLV-I or HIV were less than 1.04 x 10(3) per allogeneic unit transfused, based upon the upper 95% confidence interval of the zero incidence in this study.

Download full-text


Available from: Michael P Busch, Jun 02, 2015
7 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: Retrovirus-derived vectors provide efficient means of gene-transfer and are potential tools for therapeutic intervention against congenital or inherited disorders by in-utero gene therapy and for gene-transfer into dividing cells both in vitro and in vivo. To improve biodistribution of retroviral gene-transfer vectors and to obtain efficient gene-transfer towards hematopoietic stem cells via pre-natal administration, we performed in-utero administration of retroviral vectors pseudotyped with different envelope glycoproteins. Relatively high gene-transfer was obtained with significant differences in biodistribution and gene-transfer efficiency using various pseudotypes. There was significant reduction in the percentage of colonies containing transgene, 3 months postnatally. Next, we used HIV-derived lentiviral vectors to investigate the role of human T-lymphotropic virus type-1 (HTLV-1) accessory protein p12(I) in viral pathogenesis. HTLV-1, a deltaretrovirus cause adult T-cell leukemia/lymphoma, and other lymphocyte-mediated disorders. HTLV-1 provirus encodes various regulatory and accessory genes, including ORF-I encoded p12(I). We have demonstrated that this endoplasmic reticulum-localizing protein, increases intracellular calcium, activates NFAT-mediated transcription and is critical for infectivity in vivo and in vitro. Herein, using microarrays, we tested the role of p12(I) in regulating cellular gene expression in T-lymphocytes and found that p12(I) altered the expression of several calcium-regulated genes and genes associated with T-cell signaling, cell-proliferation and apoptosis. Furthermore, p12(I) upregulated the levels of p300 to transcriptionally significant levels, in T-lymphocytes. Next, we further characterized the mechanism of p300 upregulation by p12(I) and demonstrate that it is calcium-dependent, but calcineurin-independent. Sustained low-magnitude calcium release results in increased p300 RNA, protein and p300-mediated transcriptional activity in T-lymphocytes. Calcium-responsive p300-mediated transcription was inhibited by the p300-binding protein, adenovirus E1A, but not by p300-binding deficient E1A mutant. Additionally, ER localization of p12(I) is required for enhancing p300 levels. Collectively, our data indicate that retroviral vectors can be improved to provide effective tools for gene delivery. Using this approach, we found that HTLV-1 p12(I) modulates cellular gene expression to facilitate T-lymphocyte activation and enhances the expression of a rate-limiting co-adaptor p300 in a calcium-dependent manner. These findings provide valuable insights into the mechanisms of HTLV-1 mediated T-lymphocyte proliferation to enhance viral infectivity and clonal expansion of its genome during cell division. Title from first page of PDF file. Document formatted into pages; contains xvii, 279 p.; also includes graphics (some col.) Thesis (Ph. D.)--Ohio State University, 2004. Includes bibliographical references (p. 237-279). System requirements: World Wide Web browser and PDF viewer.
  • Source
    Michael · Bindhu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: Human T-lymphotropic virus type-1 (HTLV-1), a deltaretrovirus cause adult T-cell leukemia/lymphoma and other lymphocyte-mediated disorders. HTLV-1 provirus encodes various regulatory and accessory genes, including p30(II). Our laboratory has identified the functional properties of pX ORF-II encoded p30(II), but the role of this viral protein in virus replication or pathogenesis remains unclear. We have reported that HTLV-1 p30(II), a nuclear-localizing protein, interacts with CBP/p300, disrupts CREB-Tax-CBP/p300 complex formation at HTLV-1 Tax-Responsive Elements repeats (TRE) and differentially modulates CREB and TRE-mediated transcription. We have also recently demonstrated that p30(II) is critical in maintaining viral loads in vivo. Herein, we further characterized the role of p30(II) in regulation of cellular gene expression, using microarrays and identified alterations of interrelated pathways of cell-proliferation, T-cell signaling, apoptosis and cell-cycle in p30(II)-expressing T-lymphocytes. We are the first to test the overall effect of an HTLV-1 accessory protein, on cellular gene expression and demonstrate that p30(II) activates transcription factors involved in T-cell signaling/activation, such as NFAT, NF-KB and AP-1. We further characterized the role of p30(II) in regulation of viral gene expression, by identifying motifs critical in binding p300 and regulating TRE-mediated transcription. By analysing the amino acid domain of p30(II) critical for repressing LTR-mediated transcription, we identified a lysine residue at amino acid 106 of p30(II), that is critical for repressing TRE-mediated transcription. Additionally, we found that p300 reverses p30(II)-dependent repression of TRE-mediated transcription, in a dose-responsive manner. Our data confirms the role of p30(II) as a regulator of viral gene transcription, in association with p300. However, unlike wildtype p300, p300 HAT mutants only partially rescue p30(II)-mediated LTR repression. Additionally, p30(II) is acetylated and deacetylation enhances p30(II)-mediated LTR repression. Besides, inhibition of deacetylation decreases p30(II)-mediated LTR repression. We are the first to demonstrate that HAT activity of p300 is crucial in modulating viral gene expression from HTLV-1 LTR by p30(II). Collectively, our data indicates that HTLV-1, a complex retrovirus associated with lymphoproliferative disorders, uses accessory genes to enhance clonal expansion of the virus, avoid immune elimination and maintain proviral loads in vivo through coordinated modulation of cellular environment and tightly regulated control of viral gene expression. Title from first page of PDF file. Document formatted into pages; contains xvii, 250 p.; also includes graphics (some col.) Thesis (Ph. D.)--Ohio State University, 2004. Includes bibliographical references (p. 207-250). System requirements: World Wide Web browser and PDF viewer.
  • Source
Show more